← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	2,986	-8	-0.3%	$269B
2	2 Merck MRK $358B	2,559	+62	+2%	$156B
3	3 Pfizer PFE $168B	2,509	+66	+3%	$140B
4	4 AbbVie ABBV $501B	2,366	-46	-2%	$106B
5	5 Bristol-Myers Squibb BMY $124B	2,215	+24	+1%	$100B
6	6 Amgen AMGN $235B	2,128	+37	+2%	$113B
7	7 Gilead Sciences GILD $195B	1,537	-89	-5%	$61.8B
8	8 Novartis NVS $286B	1,118	-11	-1%	$19.7B
9	9 Regeneron Pharmaceuticals REGN $82B	907	-26	-3%	$51.6B
10	10 GSK GSK $98.2B	827	-14	-2%	$11.2B
11	11 AstraZeneca AZN $259B	724	+54	+8%	$22.4B
12	12 DELISTED Exact Sciences EXAS	517	+4	+0.8%	$14.1B
13	13 Incyte INCY $23B	501	+1	+0.2%	$18.2B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	435	-58	-12%	$31B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	389	+5	+1%	$7.77B
16	16 Exelixis EXEL $15.6B	368	-7	-2%	$6.27B
17	17 Guardant Health GH $22.3B	346	+21	+6%	$9.55B
18	18 Takeda Pharmaceutical TAK $62.1B	311	+2	+0.6%	$1.91B
19	19 NeoGenomics NEO $2.22B	294	+9	+3%	$3.76B
20	20 Halozyme HALO $13.8B	269	+4	+2%	$3.53B
21	21 Natera NTRA $58.3B	253	+34	+16%	$5.92B
22	22 Qiagen QGEN $9.53B	253	-23	-8%	$5.34B
23	23 Iovance Biotherapeutics IOVA $6.67B	252	-5	-2%	$4.61B
24	24 BeOne Medicines Ltd ONC $42.3B	244	+24	+11%	$15.7B
25	25 DELISTED Blueprint Medicines BPMC	237	+2	+0.9%	$5.29B